Our Story

Lilly Ventures has its roots in
the scientific tradition of
Eli Lilly and Company. Our
investment philosophy drives
us to seek great companies
with compelling life science innovations.

Our Team

Our collaborative partnership
leverages the collective
experience, deep expertise,
and networks of our
investment professionals for
the benefit of our portfolio
companies.

Aileron appoints Vice President of Clinical Development
September 6, 2012

Aileron Therapeutics, Inc. announced the appointment of Hubert C. Chen, M.D., to Vice President of Clinical Development, Endocrine and Metabolic Disease.

view full story

FORMA Therapeutics appoints Chief Business Officer
September 5, 2012

FORMA Therapeutics announced the appointment of Rob Sarisky, Ph.D. to Chief Business Officer. Dr. Sarisky most recently served as Vice President of Oncology Business Development and Licensing at Janssen Pharmaceuticals.

view full story

Cerulean Announces First Patient Dosed in Phase 2 Study in Ovarian Cancer
July 23, 2012

Cerulean Pharma Inc. announced that the first patient has been dosed in a Phase 2 study of its lead candidate, CRLX101, in platinum-resistant ovarian cancer patients.

view full story

Receptos Publishes G-Protein Coupled Receptor Structure in Science
July 12, 2012

Receptos Inc. announced the co-publication, with The Scripps Research Institute, of high resolution G-protein coupled receptor (GPCR) crystal structures in Science. This will enable rational drug discovery and design of GPCRs.

view full story

Cerulean Completes Enrollment of Phase 2 Study in Non-Small Cell Lung Cancer
July 2, 2012

Cerulean Pharma Inc. announced that it has completed enrollment of a randomized Phase 2 study of its lead candidate, CRLX101, in advanced non-small cell lung cancer (NSCLC) patients.

view full story

Cerulean Announces First Patient Dosed in Phase 1b/2a Study in Combination with Avastin in Renal Cancer
July 2, 2012

Cerulean Pharma Inc. announced the first patient has been dosed in a Phase 1b/2a study of its lead product candidate, CRLX101, in combination with Avastin, in metastatic renal cell carcinoma (mRCC) patients.

view full story

FORMA Therapeutics Partners with TGen Drug Development (TD2)
July 2, 2012

FORMA Therapeutics and TGen Drug Development (TD2) announced an agreement to jointly develop transformative cancer therapies, leveraging the synergistic capabilities of both organizations.

view full story

Viamet Pharmaceuticals Announces Agreement with NIAID
June 19, 2012

Viamet Pharmaceuticals, Inc. announced that it has entered into a Non-Clinical Evaluation Agreement with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). Under this agreement, Viamet will utilize NIAID’s preclinical services program to develop broad-spectrum antifungal agents.

view full story

Protagonist Therapeutics and Zealand Pharma Enter Drug Discovery Collaboration
June 18, 2012

Protagonist entered into a collaboration agreement with Zealand Pharma to identify novel peptide drug candidates by utilizing Zealand Pharma’s expertise in peptide optimization technology.

view full story